R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Additional Paid In Capital
ÂĄ1.1B
CAGR 3-Years
294%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Additional Paid In Capital
ÂĄ25.5B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Additional Paid In Capital
ÂĄ5.2B
CAGR 3-Years
-5%
CAGR 5-Years
28%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Additional Paid In Capital
ÂĄ23B
CAGR 3-Years
-5%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Additional Paid In Capital
ÂĄ10.8B
CAGR 3-Years
-3%
CAGR 5-Years
44%
CAGR 10-Years
41%
W
WuXi XDC Cayman Inc
HKEX:2268
Additional Paid In Capital
ÂĄ4.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
1.1B CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Additional Paid In Capital amounts to 1.1B CNY.

What is R&G PharmaStudies Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
294%

Over the last year, the Additional Paid In Capital growth was -2%. The average annual Additional Paid In Capital growth rates for R&G PharmaStudies Co Ltd have been 294% over the past three years .

Back to Top